Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DOSE(capstone pharm) -- Ignore unavailable to you. Want to Upgrade?

To: MARK BARGER who wrote (2)	7/30/1997 5:16:00 PM
From: Trevor Alexander Keyes	Respond to of 92

I have been following DOSe for a few months and while I think it will be a good one to own long term, I have made good amount of money just buying and selling in the 10-12 dollar range. Look at the chart -- Good Luck

To: MARK BARGER who wrote (2)	7/30/1997 11:17:00 PM
From: DGENTIL	Respond to of 92

This company was touted in a few financial magazine articles a couple of years ago. Since then, there hasn't been much interest in this company. Many some of the interest in biotechs is finally dying down.

To: MARK BARGER who wrote (2)	2/9/1998 4:56:00 PM
From: Toby Zidle	Read Replies (2) \| Respond to of 92

Lantern & Co. is cold-calling on this stock today. I just got a call from a rep at Lantern & Co. soliciting orders for DOSE. The story given is that, given a strong program of acquisitions and strong earnings announced today, the stock is about to break out with a target of $20-25 in a short time. Allegedly, DOSE is trading at a P/E that is about half of the overall industry. Earnings came out at 12 cents today which, according to Zacks (1/31), would be a penny under consensus. When I told the sales rep I wouldn't place an order on a company I hadn't checked out, the sales pitch got a bit hotter. I was told that I'd only find out info relating to past performance, but for future performance, I'd have to trust someone in the know like him. Hmmmm! Well, from reading this thread and looking at a chart, I'd conclude that DOSE may have some promise. A lot of analysts thinks so too. But DOSE sure will have a rough time getting through the $13 resistance. Rate this stock a B-. And......... let the buyer beware!